Charles River Associates CRAI yesterday announced the appointment of Elizabeth Bailey as a vice president in its Antitrust & Competition Economics Practice in its Oakland, CA office.
Bailey is known for excellence in antitrust, competition policy and intellectual property issues. She has provided economic analysis on mergers and acquisitions in the United States, Canada and Europe. She has appeared before the U.S. Department of Justice, the U.S. Federal Trade Commission and the Canadian Competition Bureau regarding numerous transactions.
She is also a frequent speaker and writer on antitrust and intellectual property. Her papers have been published in The American Economic Review, The Journal of Economic Perspectives, Review of Industrial Organization, The B.E. Journal of Economic Analysis & Policy, and Managing Intellectual Property. She serves as a senior editor for The Antitrust Law Journal, a publication of the American Bar Association’s Section of Antitrust Law. She also serves as a board member for W@Competition in the Americas.
Considering Bailey’s vast experience, the latest appointment is expected to enhance Charles River’s competitive position in Oakland.
CRA’s president and chief executive officer, Paul Maleh, stated, "We’re pleased to welcome Dr. Bailey to our team. She will greatly add to CRA’s team of skilled antitrust experts."
CRA’s Antitrust & Competition Economics Practice leader, Margaret Sanderson, stated, "Dr. Bailey is a highly-sought economic expert for merger analysis, antitrust and intellectual property matters, so we are excited to have her join our team."
Over the past year, shares of Charles River have gained 49.5%, outperforming the 43.9% growth of the industry it belongs to.
Image Source: Zacks Investment Research
Zacks Rank and Stocks to Consider
Charles River currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Some better-ranked stocks in the broader Business Services sector are Avis Budget (NASDAQ:CAR) CAR, Cross Country Healthcare (NASDAQ:CCRN) (CCRN) and Accenture (NYSE:ACN) (ACN), each sporting a Zacks Rank #1.
Avis Budget has an expected earnings growth rate of 420.6% for the current year. The company has a trailing four-quarter earnings surprise of 76.9%, on average.
Avis Budget’s shares have surged 744.3% in the past year. The company has a long-term earnings growth of 19.4%.
Cross Country Healthcare has an expected earnings growth rate of 447.8% for the current year. The company has a trailing four-quarter earnings surprise of 75%, on average.
Cross Country Healthcare’s shares have surged 201% in the past year. The company has a long-term earnings growth of 21.5%.
Accenture has an expected earnings growth rate of 19.7% for the current year. The company has a trailing four-quarter earnings surprise of 5.3%, on average.
Accenture’s shares have surged 43.2% in the past year. The company has a long-term earnings growth of 10%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Accenture PLC (ACN): Free Stock Analysis Report
Charles River Associates (CRAI): Free Stock Analysis Report
Avis Budget Group, Inc. (CAR): Free Stock Analysis Report
Cross Country Healthcare, Inc. (CCRN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research